VB Overview

Madrigal's Focus: Madrigal is concentrating on developing therapies for metabolic dysfunction associated with MASH, with its Rezdiffran drug already approved by the U.S. FDA for treating moderate to advanced fibrosis.

Financial Performance: The company reported Rezdiffran sales of $958.4 million for the full year 2025, with over 36,250 patients on the drug by the end of that year.

Expansion Plans: Madrigal has licensed global rights to six pre-clinical siRNA programs for up to $4.4 billion to expand its pipeline and is evaluating the drug for treating compensated MASH cirrhosis.

Market Reaction: Following speculation about a potential buyout by Eli Lilly, Madrigal's stock saw a significant increase, with retail sentiment shifting from neutral to extremely bullish.

Dividend Information: Vanguard Small-Cap ETF (VB) has a dividend of $0.9268, with a 30-Day SEC Yield of 1.33% as of November 30. The dividend is payable on December 24 for shareholders of record on December 22, with an ex-dividend date also on December 22.

Market Sentiment: Small-cap stocks, represented by the Vanguard Small-Cap ETF, are currently out of favor in the market, which may present compelling investment opportunities according to Seeking Alpha’s analysis.

Stock Performance: VB's share price is currently at $259.74, within a 52-week range of $190.27 to $261.76, indicating a relatively stable position near its high.

ETFs Overview: Exchange traded funds (ETFs) function like stocks, allowing investors to buy and sell units that can be created or destroyed based on demand.

Market Monitoring: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows or outflows, which can affect the underlying assets held within those ETFs.

Disclaimer: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.

Significant Inflows into Small Cap ETF: The iShares Russell 2000 ETF (IWM) experienced a remarkable inflow of $2.78 billion during the Thanksgiving week, contributing to a total of $3.7 billion added to its assets under management in November, indicating a strategic shift among investors towards small caps.

Market Dynamics and Investor Sentiment: The inflow into IWM suggests a growing conviction that small caps may outperform as expectations for rate cuts strengthen and inflation eases, especially as larger tech-focused ETFs like Invesco QQQ Trust (QQQ) faced notable outflows.

Potential for Small Cap ETFs: Other ETFs, such as the Vanguard Small-Cap ETF (VB) and Avantis U.S. Small Cap Value ETF (AVUV), are highlighted as potential vehicles for investors looking to capitalize on the anticipated resurgence of small caps, each catering to different investment strategies.

Broader Market Implications: The sudden interest in small caps may signal a shift in investor focus from mega-cap stocks to more diversified opportunities, suggesting that market participants are preparing for a potential leadership change in the equity landscape as financial conditions stabilize.

DFA's ETF Share Class Approval: Dimensional Fund Advisors has received U.S. regulatory approval to launch ETF share classes on existing mutual funds, marking the first such approval in over 20 years and allowing them to compete with Vanguard's previously patented structure.

Launch Timeline and Strategy: The approval includes 13 mutual funds, with the first ETF share classes expected to launch in early 2026, as DFA plans a gradual rollout rather than an immediate conversion of all funds.

Impact on the ETF Market: This move could significantly influence the ETF landscape, as major firms like Fidelity and Goldman Sachs are also pursuing similar applications, potentially leading to lower costs and improved tax efficiency for investors.

Industry Response: The decision has been welcomed by industry groups, highlighting its potential benefits for mutual fund shareholders and emphasizing the importance of allowing investors to choose their preferred investment wrapper based on strategy.